North America BRIC Diabetes Care Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America BRIC Diabetes Care Devices Market: by Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices, Continuous Glucose Monitoring Devices, Smart Insulin Pens, Diabetes Management Apps, Others), Application (Self/Home Care, Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Academic & Research Institutions, Others), Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Diabetes Clinics, Supermarkets/Hypermarkets, Others), Technology (Wearable Technology, Non-invasive Technology, Smartphone-connected Devices, Implantable Devices, Traditional Devices, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20340
North America BRIC Diabetes Care Devices Market: 2025–2035 Outlook
The North America BRIC Diabetes Care Devices market encompasses a wide range of innovative solutions aimed at enhancing diabetes management and improving patient outcomes. This market includes blood glucose monitoring devices, insulin delivery systems, continuous glucose monitoring (CGM) tools, smart insulin pens, and advanced management apps. The rising prevalence of diabetes, increasing health awareness, and rapid technological advancements are key forces shaping this sector. As a result, healthcare providers and patients are turning increasingly to digital solutions and next-generation devices. The drive towards remote patient monitoring, the emergence of non-invasive technologies, and a focus on user-friendly, integrated devices further accelerate market growth.
Latest Market Dynamics
Key Drivers
Rapid adoption of continuous glucose monitoring (CGM) systems: In 2025, Dexcom’s latest G7 CGM launch supports the trend towards real-time data and improved glycemic control, leading to broader acceptance among healthcare professionals and patients.
Growth in smartphone-connected diabetes management: Abbott Laboratories’ FreeStyle Libre app integration delivers actionable insights, empowering patients with seamless device interactivity and personal diabetes data tracking.
Key Trends
Expansion of wearable technology in diabetes care: Medtronic’s MiniMed 780G system highlights the move toward closed-loop solutions for automated insulin delivery, as patients and providers demand integrated, low-effort management tools.
Rising integration of AI and big data analytics: Companies like Tandem Diabetes Care are embedding AI algorithms to optimize insulin dosing and predict glucose trends, driving the industry toward smarter, data-driven care models.
Non-invasive glucose monitoring advancements: Senseonics Holdings and others are investing in implantable and needle-free solutions, addressing user discomfort and boosting adoption for those reluctant to use traditional finger-prick devices.
Telehealth and remote diabetes management: Rising demand for remote patient monitoring, driven by cross-platform apps and CGM data integration (e.g., Insulet’s Omnipod 5), opens new growth avenues in care continuity and personalized treatment.
Key Challenges
Integration across multiple platforms: Manufacturers face challenges ensuring device compatibility across various smartphones and EHR systems, as seen with interoperability hurdles reported by Ascensia Diabetes Care.
Data privacy and security concerns: With rising digital device usage, providers like Johnson & Johnson are investing in cybersecurity to address regulatory and patient trust issues over health data management.
Key Restraints
High cost of advanced devices: Premium pricing of CGMs and smart insulin pens remains a barrier in underinsured populations, with price sensitivity limiting access despite innovations by major players like Medtronic.
Complex reimbursement landscape: Varied insurance coverage for next-generation devices delays broader adoption, as exemplified by ongoing reimbursement negotiations involving Becton Dickinson and newer digital entrants.
North America BRIC Diabetes Care Devices Market Share by Type, 2025
In 2025, continuous glucose monitoring devices are projected to command the largest market share in North America, reflecting an accelerating shift from traditional blood glucose meters towards real-time, data-driven management solutions. Blood glucose monitoring devices continue to be a core part of diabetes care, while the uptake of smart insulin pens and digital management apps is increasing due to patient demand for convenience and connectivity. Insulin delivery devices also maintain significant market presence as personalized dosing and advanced delivery systems become embedded into standard care routines.
North America BRIC Diabetes Care Devices Market Share by Application, 2025
Self and home care remain dominant in the diabetes device application segment in North America, capturing the largest share in 2025. The convenience of monitoring at home, coupled with rising adoption of digital self-management platforms, drives this preference. Hospitals and clinics follow, as advanced devices support complex patient needs in clinical settings. Diagnostic centers and ambulatory surgical centers make up a smaller percentage, while research and academic institutions are primarily focused on device trials, validation, and training.
North America BRIC Diabetes Care Devices Market Revenue, 2020–2035 (USD Million)
The North America BRIC Diabetes Care Devices market has shown robust revenue growth, increasing steadily year-on-year from 2020 to 2035, driven by greater disease prevalence and technology adoption. In 2025, revenue is estimated at $3,800 million and is forecast to reach over $8,700 million by 2035. This growth reflects both increased device penetration in outpatient and home settings, and the rapid uptake of advanced monitoring and delivery systems. Market expansion is sustained by ongoing healthcare digitization and a strong shift towards personalized, real-time diabetes management.
North America BRIC Diabetes Care Devices Market Year-over-Year Growth, 2020–2035 (%)
Year-on-year growth for the North America BRIC Diabetes Care Devices market is projected to range between 7% and 11% from 2020 to 2030, with a slightly moderated pace as the market matures towards 2035. The highest growth is expected around 2025, coinciding with regulatory approvals of next-generation CGMs and smart delivery systems. The growth rate normalizes as device adoption becomes mainstream and market penetration increases across both clinical and home care applications.
North America BRIC Diabetes Care Devices Market Share by Country, 2025
In 2025, the US will continue to dominate the North America BRIC Diabetes Care Devices market by share, attributed to its large diabetic population, advanced healthcare infrastructure, and willingness to adopt new technologies. Canada and Mexico trail behind, benefitting from increasing healthcare investments and gradual regulatory alignment with US standards, yet facing slower adoption rates compared to the US.
North America BRIC Diabetes Care Devices Market Share by Top Players, 2025
Medtronic, Abbott Laboratories, and Dexcom jointly hold the largest portion of the North America BRIC Diabetes Care Devices market in 2025. Their dominance is driven by robust R&D pipelines, extensive product portfolios, and established distribution networks. Other leading participants, including Becton Dickinson, Johnson & Johnson, and Roche, also secure significant shares owing to continuous innovation and strategic partnerships. The market remains moderately fragmented beyond the top firms due to the entry of digital-native companies.
North America BRIC Diabetes Care Devices Market Share by Buyers, 2025
Individual consumers represent the largest share of device buyers in North America, propelled by the growth in at-home diabetes management and increased awareness. Hospitals and clinics also make up a substantial portion, purchasing advanced devices for inpatient and outpatient care. Other buyer groups, including pharmacies and research institutions, account for smaller but rising shares, driven by the expanding role of digital therapeutics and training programs.
Medtronic, Abbott Laboratories, F. Hoffmann-La Roche AG, Dexcom, Becton Dickinson, Johnson & Johnson, Ascensia Diabetes Care, Insulet Corporation, Tandem Diabetes Care, Senseonics Holdings, Ypsomed, Sanofi, Novo Nordisk, Eli Lilly and Company, Terumo Corporation
Key Recent Developments
June 2024: Dexcom launches G7 CGM in North America, emphasizing expanded integration with major health apps.
July 2024: Abbott secures FDA approval for its first over-the-counter CGM sensor, broadening access for Type 2 diabetes patients.
August 2024: Medtronic announces a partnership with Apple to enable seamless data sharing from MiniMed pumps to iOS devices.
September 2024: Insulet unveils Omnipod 5 for pediatric populations in Canada, featuring advanced algorithm-based insulin delivery.
October 2024: Tandem Diabetes Care rolls out new t:slim X2 software with AI-based dosing for enhanced glycemic outcomes.
